(1E,4E)-1-(1-(sec-Butyl)-1H-imidazol-2-yl)-5-(pyridin-2-yl)penta-1,4-dien-3-one

ID: ALA4211207

PubChem CID: 145964784

Max Phase: Preclinical

Molecular Formula: C17H19N3O

Molecular Weight: 281.36

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCC(C)n1ccnc1/C=C/C(=O)/C=C/c1ccccn1

Standard InChI:  InChI=1S/C17H19N3O/c1-3-14(2)20-13-12-19-17(20)10-9-16(21)8-7-15-6-4-5-11-18-15/h4-14H,3H2,1-2H3/b8-7+,10-9+

Standard InChI Key:  SXZZPBMQCZOGNL-XBLVEGMJSA-N

Molfile:  

     RDKit          2D

 21 22  0  0  0  0  0  0  0  0999 V2000
   17.1175  -12.6805    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8319  -12.2680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8319  -11.4430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5464  -11.0305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5464  -10.2055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1175  -11.0305    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.2609   -9.7930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2609   -8.9680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9754   -8.5555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6898   -8.9680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6898   -9.7930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9754  -10.2055    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.1175  -13.5055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7849  -13.9904    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.5300  -14.7750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7050  -14.7750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4500  -13.9904    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.6654  -13.7354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4939  -12.9285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7093  -12.6735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0523  -14.2875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  3  6  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
  7 12  2  0
  5  7  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 13 17  1  0
 18 19  1  0
 19 20  1  0
 18 21  1  0
 17 18  1  0
  1 13  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4211207

    ---

Associated Targets(Human)

PC-3 (62116 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DU-145 (51482 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LNCaP (8286 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PWR-1E (93 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 281.36Molecular Weight (Monoisotopic): 281.1528AlogP: 3.54#Rotatable Bonds: 6
Polar Surface Area: 47.78Molecular Species: NEUTRALHBA: 4HBD:
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 6.02CX LogP: 3.47CX LogD: 3.45
Aromatic Rings: 2Heavy Atoms: 21QED Weighted: 0.76Np Likeness Score: -0.93

References

1. Zhang X, Guo S, Chen C, Perez GR, Zhang C, Patanapongpibul M, Subrahmanyam N, Wang R, Keith J, Chen G, Dong Y, Zhang Q, Zhong Q, Zheng S, Wang G, Chen QH..  (2017)  Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies.,  137  [PMID:28601720] [10.1016/j.ejmech.2017.05.062]

Source